Company Overview

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors, including non-small cell lung cancer (NSCLC) and ovarian cancer.

Stock Snapshot

NASDAQ:

DMPI

Price

Loading...

Change

Loading...

Volume

Loading...

Market Cap

Loading...

52 week Low/High

Loading...

Day Low/High

Loading...

Latest Financial Results

2016

Year End Results

Ended Jun 30, 2016

Contact Information

Investor Relations
T: (604) 629-5989
ir@delmarpharma.com

Transfer Agent
Island Stock Transfer
15500 Roosevelt Blvd
Suite 301
Clearwater, FL 33760
T: 727-289-0010